Threshold bags $12.5M milestone from Merck KGaA; Neuralstem raises $20M; Top execs leave troubled Marina;

@FierceBiotech: Marina Biotech, Mirna Therapeutics amend license deal to develop microRNA-based therapeutics. Release | Follow @FierceBiotech

@JohnCFierce: Top FierceBiotech story yesterday: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. More | Follow @JohnCFierce

@DamianFierce: The long, strange trip that was Wright Medical's 2013. Report | Follow @DamianFierce

@EmilyMFierce: Cancer Research UK to repurpose an AstraZeneca asthma drug for kidney cancer. Story from FierceBiotech Research | Follow @EmilyMFierce

> Threshold Pharmaceuticals ($THLD) has earned a $12.5 million payment from Merck KGaA after enrollment in a trial of the cancer drug TH-302 hit 620 subjects. Story

> Rockville, MD-based Neuralstem ($CUR) raised close to $20 million through the sale of company stock. Release

> Troubled RNAi player Marina Biotech says that in a cost-cutting move its CFO and head of R&D have resigned from their positions. Interim CFO Philip Ranker is joining the board while Richard Ho becomes chair of the company's SAB. Release

Medical Device News

@FierceMedDev: The CFO of troubled Mela Sciences resigned on Dec. 31. CEO Rose Crane is filling in. Release | Follow @FierceMedDev

@MichaelGFierce: Gene therapy technique from Washington University in St. Louis targets tumor blood vessels. Article | Follow @MichaelGFierce

@GalenMoore: Drug companies accused of holding back complete information on clinical trials. Story | Follow @GalenMoore

> Nipro is recalling glucose meters over a display mixup. More

> Quidel entices investors with FDA thumbs-up for strep test. News

> Boston Scientific looks to follow up on a big 2013. Report

Pharma News

@FiercePharma: Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets. Release | Follow @FiercePharma

@EricPFierce: Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M. More | Follow @EricPFierce

@CarlyHFierce: Cue more drama in Teva's boardroom as its CEO announcement nears. Yesterday's story | Follow @CarlyHFierce

> Bayer's hot-selling Eylea runs into a roadblock in its home market. Story

> Mylan has hired away a new India president from Biocon, its partner there. Report

> China clears hep B vaccine makers in child deaths. More

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.